Latran, 2 mg/ml 4 ml 5 pcs

• prevention, prevention and elimination of nausea and vomiting in the postoperative period;
• symptomatic treatment of alcohol withdrawal syndrome (especially of mild to moderate severity).
• Nausea and vomiting caused by x-ray, radio- or chemotherapy with anticancer drugs or exposure to ionizing radiation;

.

Indications

prevention, prevention and elimination of nausea and vomiting in the postoperative period;
symptomatic treatment of alcohol withdrawal syndrome (especially mild and moderate severity).
nausea and vomiting caused by x-ray, radio or chemotherapy with antitumor drugs or exposure to ionizing radiation;

Pharmacological effect

Latran has an antiemetic and anti-withdrawal effect.

Special instructions

Patients with signs of intestinal obstruction after using the drug require regular monitoring, because ondansetron may cause constipation.

The infusion solution must be prepared immediately before use. If necessary, the prepared infusion solution can be stored until use for a maximum of 24 hours at a temperature of 2–8 °C.

Hypersensitivity reactions when using Latran® may occur in patients previously observed for similar reactions when using other selective 5-HT3 receptor antagonists.

No protection from light is required during the infusion: the diluted injection solution remains stable for at least 24 hours in natural light or normal lighting.

Active ingredient

Ondansetron

Composition

Active ingredient:

ondansetron hydrochloride dihydrate (based on base) 2 mg;

Excipients:

sodium chloride;

hydrochloric acid;

water for injections;

Contraindications

pregnancy;
breast-feeding;
hypersensitivity to any component of the drug;
children under 2 years of age (safety and effectiveness of use in Russia have not been studied).

Side Effects

From the gastrointestinal tract: hiccups, dry mouth, diarrhea, constipation, sometimes asymptomatic transient increases in the level of aminotransferases in the blood serum.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

From the nervous system: headache, dizziness, spontaneous movement disorders and convulsions.

From the cardiovascular system: chest pain, in some cases with ST segment depression, bradycardia, arrhythmias, arterial hypotension.

Other: local reactions (pain, burning and redness at the injection site), flushing of the face, feeling of heat, temporary impairment of visual acuity, hypokalemia.

Interaction

Since ondansetron is metabolized by the liver enzyme system (cytochrome P450), caution is required when used together:

– with P450 enzymatic inducers (CYP2D6 and CYP3A) (barbiturates, carbamazepine, carisoprodol, glutethimide, griseofulvin, nitrous oxide, papaverine, phenylbutazone, phenytoin and probably other hydantoins, rifampicin, tolbutamide);

– with inhibitors of P450 enzymes (CYP2D6 and CYP3A) (allopurinol, macrolide antibiotics, antidepressants – MAO inhibitors, chloramphenicol, cimetidine, estrogen-containing oral contraceptives, diltiazem, disulfiram, erythromycin, valproic acid, sodium valproate, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranolol, quinidine, quinine, verapamil).

Overdose

In cases of suspected overdose, symptomatic therapy is indicated.

In case of overdose, the use of ipecac is not recommended, because It is unlikely that this drug will be effective during the period of antiemetic action of Latran®.

A specific antidote is not known.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

FSUE Pharmzaschita NPC, Russia